These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E; J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550 [TBL] [Abstract][Full Text] [Related]
29. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936 [TBL] [Abstract][Full Text] [Related]
30. Bortezomib and its role in the management of patients with multiple myeloma. Orlowski RZ Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047 [TBL] [Abstract][Full Text] [Related]
31. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495 [TBL] [Abstract][Full Text] [Related]
32. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Niesvizky R; Richardson PG; Rajkumar SV; Coleman M; Rosiñol L; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Boral AL; Esseltine DL; Anderson KC; Bladé J Br J Haematol; 2008 Oct; 143(1):46-53. PubMed ID: 18673366 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408 [TBL] [Abstract][Full Text] [Related]
34. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077 [TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients. Quach H; Horvath N; Cannell P; Mikhael JR; Butcher BE; Prince HM Intern Med J; 2009 May; 39(5):290-5. PubMed ID: 19371392 [TBL] [Abstract][Full Text] [Related]
36. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779 [TBL] [Abstract][Full Text] [Related]
37. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586 [TBL] [Abstract][Full Text] [Related]
38. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial. O'Connor OA; Moskowitz C; Portlock C; Hamlin P; Straus D; Dumitrescu O; Sarasohn D; Gonen M; Butos J; Neylon E; Hamelers R; Mac-Gregor Cortelli B; Blumel S; Zelenetz AD; Gordon L; Wright JJ; Vose J; Cooper B; Winter J Br J Haematol; 2009 Apr; 145(1):34-9. PubMed ID: 19220284 [TBL] [Abstract][Full Text] [Related]
39. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Ludwig H; Khayat D; Giaccone G; Facon T Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]